Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 8:01 PM
Ignite Modification Date:
2025-12-24 @ 8:01 PM
NCT ID:
NCT03173404
Eligibility Criteria:
Inclusion Criteria:
* Women with infertility / primary infertility.
* Women who are about to start an IVF/ICSI cycle with their own eggs.
* Age greater than or equal to 18 years and less than or equal to 40 years.
* Women in whom a multiple follicular development will be developed with a short protocol with antagonists or long with agonists, and starting dose of gonadotropins according to clinical criteria.
* Women with uterine ultrasound without endometrial pathology
Exclusion Criteria:
* Ovarian reserve: Antimullerian hormone \<0.5 ng / dl or Count of antral follicles \<5 between both ovaries.
* Myomatous uterus: presence of\> 2 myomas\> 4cm or that deform uterine cavity.
* Uterine malformations.
* Body mass index (BMI) \<18 or\> 30.
* Polycystic ovarian syndrome: according to European Society of Human Reproduction and Embryology (ESRHE)/Rotterdam 2003 criteria.
* Moderate-severe endometriosis.
* Background or presence of pelvic inflammatory disease.
* Hydrosalpinx not excised or occluded.
* Hyperprolactinemia, defined as prolactin levels greater than 50 ng / ml.
* Diagnostic history of endometrial hyperplasia.
* Severe male factor: severe oligoasthenoteratozoospermia with a sperm cell count (REM) \<100,000 spermatozoa / ml.
* Impossibility to apply the treatments provided by the study in the terms established by the protocol.
* Contraindication for the use of any of the treatments provided in the study.
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
40 Years
Study:
NCT03173404
Study Brief:
Protocol Section:
NCT03173404